Hims & Hers Health (STU:82W) Research & Development: €143 Mil (TTM As of Mar. 2026)


STU:82W Hims & Hers Health Inc STU:82W
69 GF Score
Price €31.58
GF Value €34.36
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Hims & Hers Health Research & Development?

Hims & Hers Health STU:82W -0.44% 69 Research & Development is €143 Mil as of Mar. 2026. GuruFocus rates STU:82W with a GF Score™ of 69/100 and a GF Value™ of €34.36 (Fairly Valued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Hims & Hers Health's Research & Development for the three months ended in Mar. 2026 was €41 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €143 Mil.

Hims & Hers Health  (STU:82W) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hims & Hers Health Research & Development Related Terms

Hims & Hers Health Research & Development Historical Data

* Premium members only.

The historical data trend for Hims & Hers Health's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hims & Hers Health Research & Development Chart

Hims & Hers Health Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 19.81 27.60 44.22 75.27 127.50

Hims & Hers Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.67 32.81 34.57 34.98 40.60
STU:82W
69GF Score
Hims & Hers Health Inc STU:82W
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hims & Hers Health Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €143 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €143 Mil mean?
Hims & Hers Health (STU:82W) has a Research & Development of €143 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Hims & Hers Health and its competitors.
Is Hims & Hers Health's Research & Development too high?
Hims & Hers Health's current Research & Development is €143 Mil. Overall, Hims & Hers Health has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Hims & Hers Health's Research & Development compare to LNTH and LQDA?
Hims & Hers Health's Research & Development of €143 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hims & Hers Health and its competitors. Hims & Hers Health's current Research & Development is €143 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hims & Hers Health stock overvalued right now?
Based on GuruFocus' analysis, Hims & Hers Health (STU:82W) is currently considered Fairly Valued. The stock's GF Value™ is €34.36, compared to a current price of €31.58 — trading 8.1% below its estimated fair value. The current Research & Development is €143 Mil. Hims & Hers Health's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hims & Hers Health (STU:82W), the current Research & Development is €143 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hims & Hers Health (STU:82W) Overvalued in 2026?

Based on GuruFocus' analysis, Hims & Hers Health stock appears to be undervalued. The current stock price of €31.58 is trading 8.1% below its estimated GF Value™ of €34.36. GuruFocus considers Hims & Hers Health to be Fairly Valued.

Key valuation signals for STU:82W:

  • Research & Development: €143 Mil
  • GF Value™: €34.36 vs. price of €31.58 (8.1% below fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the STU:82W stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hims & Hers Health Business Description

Other Exchanges HIMS:USAHIMS:Mexico
Address 2269 Chestnut Street, No. 523, San Francisco, CA, USA, 94123
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
69GF Score

Get the complete analysis for STU:82W

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.58
Price
€34.36
GF Value